T cell costimulatory pathways: blockade for autoimmunity

Bibliography

• REISER H, STADECKER MJ: Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl. J. Med. (1996) 335:1369–1377.
   PubMed Web of Science ®Google Scholar
• SAYEGH MH, TURKA LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl. I Med. (1998) 338:1813–1821.
   PubMed Web of Science ®Google Scholar
• BRETCHER P, COHN M: A theory of self-nonself discrimination. Science (1970) 169:1042–1049.
   PubMed Web of Science ®Google Scholar
• YAMADA A, SALAMA AD, SAYEGH MH: The role of novel T cell costimulatory pathways in autoimmunity and transplantation. I Am. Soc. Nephrol. (2002) 13:559–575.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, LEDBETTER JA: The role of the CD28 receptor during T cell responses to antigen. Anna. Rev Immunol (1993) 11:191–212.
   PubMed Web of Science ®Google Scholar
• JUNE CH, BLUESTOME JA, NADLER LM, THOMPSON CB: The B7 and CD28 receptor families. Immunol. Today (1994) 15:321–331.
   PubMedGoogle Scholar
• NAJAFIAN N, SAYEGH MH: CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Investig. Drugs (2000) 9:2147–2157.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of CTLA-4-Ig.
   Google Scholar
• RILEY J, MAO M, KOBA YASHI S et al.:Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, andCTLA-4 receptors. Proc. Natl. Acad. Sci. USA (2002) 99:11796–11801.
   Google Scholar
• DIEHN M, ALIZADEH AA, RANDO OJet al: Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. USA (2002) 99:11790–11795.
   PubMedGoogle Scholar
• •Gene expression studies to evaluate the role of CD28 costimulation in T cell activation.
   Google Scholar
• LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBETTER JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. (1991) 174:561–569.
   PubMed Web of Science ®Google Scholar
• WALUNAS TL, BAKKER CY,BLUESTONE JA: CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in I Exp. Med. (1996) 184(1):301] J. Exp. Med. (1996) 183:2541–2550.
   Google Scholar
• TIVOL EA, BORRIELLO F, SCHWEIZER AN, LYNCH WP, BLUESTONE JA, SHARPE AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3:541–547.
   PubMed Web of Science ®Google Scholar
• GUINAN EC, GRIBBEN JG, BOUSSIOTIS VA, FREEMAN GJ, NADLER LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood (1994) 84:3261–3282.
   PubMed Web of Science ®Google Scholar
• WALUNAS TL, LENSCHOW DJ, BAKKER CY et al.: CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 1:405–413.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, GREENE JL, BRADY W, BAJORATH J, LEDBETTER JA, PEACH R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 1:793–801.
   PubMed Web of Science ®Google Scholar
• NOEL PJ, BOISE LH, GREEN JM, THOMPSON CB: CD28 costimulation prevents cell death during primary T cell activation. Immunol. (1996) 157:636–642.
   Web of Science ®Google Scholar
• GIMMI CD, FREEMAN GJ, GRIBBEN JG, GRAY G, NADLER LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA (1993) 90:6586–6590.
   PubMed Web of Science ®Google Scholar
• VAN PARIJS L, ABBAS AK: Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science (1998) 280:243–248.
   PubMed Web of Science ®Google Scholar
• PEREZ VL, VAN PARIJS L, BIUCKIANS A, ZHENG XX, STROM TB, ABBAS AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity\(1997) 6:411–417.
   PubMed Web of Science ®Google Scholar
• LUHDER F, HOGLUND P, ALLISON JP, BENOIST C, MATHIS D: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. (1998) 187:427–432.
   PubMed Web of Science ®Google Scholar
• KARANDIKAR NJ, VANDERLUGT CL, WALUNAS TL, MILLER SD, BLUESTONE JA: CTLA-4: a negativeregulator of autoimmune disease. J. Exp. Med. (1996) 184:783–788.
   PubMed Web of Science ®Google Scholar
• GREENWALD RS, LATCHMAN YE, SHARPE AH: Negative co-receptors on lymphocytes. Curt Opin. Immunol. (2002) 14:390–396.
   Google Scholar
• ••Excellent review of negative costimulatorypathways on lymphocytes.
   Google Scholar
• GUERDER S, PICARELLA DE, LINSLEY PS, FLAVELL RA: Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA (1994) 91:5138–5142.
   PubMed Web of Science ®Google Scholar
• HARLAN DM, HENGARTNER H, HUANG ML et al.: Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Set USA (1994) 91:3137–3141.
   PubMed Web of Science ®Google Scholar
• WILLIAMS IR, ORT RJ, KUPPER TS: Keratinocyte expression of B7-1 in transgenic mice amplifies the primary immune response to cutaneous antigens. Proc. Natt Acad. Sci. USA (1994) 91:12780–12784.
   PubMed Web of Science ®Google Scholar
• WINDHAGEN A, NEWCOMBE J, DANGOND F et al: Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp. Med. (1995) 182:1985–1996.
   PubMed Web of Science ®Google Scholar
• RANHEIM EA, KIPPS TJ: Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis [see comments]. Arthritis Rheum. (1994) 37:1637–1646.
   PubMed Web of Science ®Google Scholar
• SIMON JC, DIETRICH A, MIELKE V et al.: Expression of the B7/BB1 activation antigen and its ligand CD28 in T- cell-mediated skin diseases. J. Invest. Dermatol (1994) 103:539–543.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, NESTLE FO,ZHENG XG, TURKA LA: T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28. Blood (1994) 83:2580–2586.
   PubMed Web of Science ®Google Scholar
• FIELDS LE, LOH DY: Organ injury associated with extrathymic induction of immune tolerance in doubly transgenic mice. Proc. Natl. Acad. Sci. USA (1992) 89:5730–5734.
   PubMed Web of Science ®Google Scholar
• SCHONRICH G, KALINKE U, MOMBURG F et al.: Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Ce//(1991) 65:293–304.
   Google Scholar
• LO D, BURKLY LC, WIDERA G et al: Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic beta cells. Cell (1988) 53:159–168.
   PubMed Web of Science ®Google Scholar
• LO D, BURKLY LC, FLAVELL RA, PALMITER RD, BRINSTER RL: Tolerance in transgenic mice expressing class II major histocompatibility complex on pancreatic acinar cells. J Exp. Med. (1989) 170:87–104.
   PubMed Web of Science ®Google Scholar
• DURIE FH, FOY TM, MASTERS SR, LAMAN JD, NOELLE RJ: The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today (1994) 15:406–411.
   PubMedGoogle Scholar
• HANCOCK WW, SAYEGH MH, ZHENG XG, PEACH R, LINSLY PS, TURKA LA: Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Nati Acad. Sci. USA (1996) 93:13967–13972.
   PubMed Web of Science ®Google Scholar
• RANHEIM EA, KIPPS TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. I. Exp. Merl (1993) 177:925–935.
   PubMed Web of Science ®Google Scholar
• GUO Y, WU Y, SHINDE S, SY MS, ARUFFO A, LIU Y: Identification of a costimulatory molecule rapidly induced by CD4OL as CD44H. J. Exp. Med. (1996) 184:955–961.
   PubMed Web of Science ®Google Scholar
• YELLIN MJ, D& AGATI V,PARKINSON G et al.: Immunohistologic analysis of renal CD40 and CD4OL expression in lupus nephritis and other glomerulonephritides. Arthritic Rheum. (1997) 40:124–134.
   Google Scholar
• WHITMIRE JK, AHMED R: Costimulation in antiviral immunity: differential requirements for CD4(+) and CD8(+) T cell responses. Curt Opin. Immunol (2000) 12:448–455.
   PubMed Web of Science ®Google Scholar
• LENSHOW DJ, HEROLD KC, RHEE L et al: CD28/B7 regulation of Thl and Th2 subsets in the development of autoimmune diabetes [published erratum appears in Immunity (1997) 6(2):following 215]. Immunity (1996) 5:285–293.
   PubMed Web of Science ®Google Scholar
• CHANG TT, JABS C, SOBEL RA, KUCHROO VK, SHARPE AH: Studies in
   Google Scholar
• B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp. Med. (1999) 190:733–740.
   PubMed Web of Science ®Google Scholar
• LONDON CA, LODGE MP, ABBAS AK: Functional responses and costimulator dependence of memory CD4+ T cells. J. Immunol (2000) 164:265–272.
   PubMed Web of Science ®Google Scholar
• COYLE AJ, GUTIERREZ-RAMOS JC: The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. (2001) 2:203–209.
   PubMed Web of Science ®Google Scholar
• HUTLOFF A, DITTRICH AM, BEIER KC et al.: ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 397:263–266.
   PubMed Web of Science ®Google Scholar
• ••Identifies ICOS as a CD28 homologue onactivated human T cells and shows that, in conjuction with a TCR signal, IC OS crosslinking upregulates cytokine production, particularly of IL-10, but not IL–2.
   Google Scholar
• DONG C, JUEDES AE, TEMANN UA et al.: ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 409:97–101.
   PubMed Web of Science ®Google Scholar
• •Shows that myelin oligodendrocyte glycoprotein-induced EAE is greatly exacerbated in ICOS knockout mice as compared with wild type mice.
   Google Scholar
• MCADAM AJ, GREENWALD RJ, LEVIN MA et al: ICOS is critical for CD40-mediated antibody class switching. Nature (2001) 409:102–105.
   PubMed Web of Science ®Google Scholar
• ••Shows the crucial role for ICOS inregulating irmrtunoglobulin isotype class switching and in germinal centre formation.
   Google Scholar
• TAFURI A, SHAHINIAN A, BLADT F et al: ICOS is essential for effective T-helper-cell responses. Nature (2001) 409:105–109.
   PubMed Web of Science ®Google Scholar
• SWALLOW MM, WALLIN JJ, SHA WC: B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity (1999) 11:423–432.
   Google Scholar
• YOSHINAGA SK, ZHANG M, PISTILLO J et al: Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int. Immunol (2000) 12:1439–1447.
   PubMed Web of Science ®Google Scholar
• AICHER A, HAYDEN-LEDBETTER M, BRADY WA et al.: Characterization of human inducible costimulator ligand
   Google Scholar
• ••expression and function. j. Immunol (2000) 164:4689–4696.
   Google Scholar
• AGATA Y, KAWASAKI A,NISHIMURA H et al.: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunal (1996) 8:765–772.
   Google Scholar
• LATCHMAN Y, WOOD CR, CHERNOVA T et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. (2001) 2:261–268.
   PubMed Web of Science ®Google Scholar
• ••Identifies a B7 homologue as a second receptor for PD–1.
   Google Scholar
• FREEMAN GJ, LONG AJ, IWAI Yet al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. (2000) 192:1027–1034.
   Google Scholar
• ••Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
   Google Scholar
• NISHIMURA H, NOSE M, HIAI H, MINATO N, HONJO T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity (1999) 11:141–151.
   PubMed Web of Science ®Google Scholar
• LECHNER 0, LAUBER J, FRANZKE A, SARUKHAN A, VON BOEMER H, BUER J: Fingerprints of anergic T cells. Curc Biol. (2001) 11:587–595.
   PubMedGoogle Scholar
• GAVIN MA, CLARKE SR, NEGROU E, GALLEGOS A, RUDENSKY A: Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat. Immunal (2002) 3:33–41.
   Google Scholar
• HARLAN DM, ABE R, LEE KP, JUNE CH: Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. Clin. Immunal Immunopathol (1995) 75:99–111.
   PubMed Web of Science ®Google Scholar
• FINCK BK, LINSLEY PS, WOFSY D: Treatment of murine lupus with CTLA4Ig. Science (1994) 265:1225–1227.
   PubMed Web of Science ®Google Scholar
• REYNOLDS J, TAM FW, CHANDRAKER A et al: CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. Clin. Invest. (2000) 105:643–651.
   Google Scholar
• LENSCHOW DJ, HO SC, SATTAR H et al.: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in thenonobese diabetic mouse. J. Exp. Med.(1995) 181:1145–1155.
   PubMed Web of Science ®Google Scholar
• RACKE MK, SCOTT DE, QUIGLEY L et al.: Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.Clin. Invest. (1995) 96:2195–2203.
   Google Scholar
• SCHAUB M, ISSAZADEH S, STADLBAUR TH, PEACH R, SAYEGH MH, KHOURY SJ: Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. Neuraimmuna (1999) 96:158–166.
   PubMed Web of Science ®Google Scholar
• KHOURY SJ, AKALIN E, CHANDRAKER A et al.: CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Thl but spares Th2 cytokines in the central nervous system. J. Immunul. (1995) 155:4521–4524.
   PubMed Web of Science ®Google Scholar
• TANG A, JUDGE TA, NICKOLOFF BJ, TURKA LA: Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand.Immunol (1996) 157:117–125.
   Google Scholar
• TANG A, JUDGE TA, TURKA LA: Blockade of CD4O-CD40 ligand pathway induces tolerance in murine contact hypersensitivity. Eur. I Immunal (1997) 27:3143–3150.
   PubMed Web of Science ®Google Scholar
• KEARNEY ER, WLUNAS TL, KARR RW et al.: Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. I Immunal (1995) 155:1032–1036.
   PubMed Web of Science ®Google Scholar
• JUDGE TA, WU Z, ZHENG XG, SHARPE AH, SAYEGH MH, TURKA LA: The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. Immunol(1999) 162: 1947-1951.
   Google Scholar
• KUCHROO VK, DAS MP, BROWN JA et al.: B7-1 and B7-2 costimulatory molecules differentially activate the TH1/ TH2 developmental pathways: application to autoimmune disease therapy. Cell(1995) 80:707–718.
   PubMed Web of Science ®Google Scholar
• DAIKH DI, WOFSY D: Effects of anti-B7monoclonal antibodies on humoral immune responses. J. Autuimmunih, (1999) 12:101–108.
   PubMed Web of Science ®Google Scholar
• BALASA B, KRAHL T, PATSTONE G et al.: CD40 ligand-CD40 interactions arenecessary for the initiation of insulitis and diabetes in nonobese diabetic mice.Immunal (1997) 159:4620–4627.
   PubMed Web of Science ®Google Scholar
• GERRITSE K, LAMAN JD, NOELLE RJ et al.: CD4O-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA (1996) 93:2499–2504.
   PubMed Web of Science ®Google Scholar
• HOWARD LM, MIGA AJ, VANDERLUGT CL et al: Mechanisms of immunotherapeutic intervention by anti-CD4OL (CD154) antibody in an animal model of multiple sclerosis. Clin. Invest.(1999) 103:281–290.
   Google Scholar
• KOSHY M, BERGER D, CROW MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.Gin. Invest. (1996) 98:826–837.
   PubMed Web of Science ®Google Scholar
• DAIKH DI, FINCK BK, LINSLEY PS, HOLLENBAUGH D, WOFSY D: Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.Immunal (1997) 159:3104–3108.
   PubMed Web of Science ®Google Scholar
• SPORICI RA, BESWICK RL, VON ALLMAN C et al.: ICOS ligand costimulation is required for T-cell encephalitogenicity. Cliii. Immunol(2001) 100:277–288.
   Google Scholar
• ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediatedblockade of T-cell costimulation in patients with psoriasis vulgaris. Clin. Invest.(1999) 103:1243–1252.
   Google Scholar
• MORELAND LW ALTEN R, VAN DEN BOSCH F et al: Costimulatory blockade in patients with rheumatoid arthritis. Arthritic Rheum. (2002) 46:1470–1479.
   PubMed Web of Science ®Google Scholar
• KAWAI T, ANDREWS D, COLVIN RB, SACHS DH, COSIMI AB:Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. (2000) 6:114.
   Web of Science ®Google Scholar
• KALUNIAN KC, DAVIS JC,MERRILL JT, TOTORITIS MC, WOFSY D: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD i54. Arthritic Rheum. (2002) 12:3251–3258.
   Google Scholar
• •First clinical study that evaluates the safety and efficacy of a humanised mAb against CD154 in patients with active SLE.
   Google Scholar
• SAYEGH MH: Finally, CTLA4Ig graduatesto the clinic. J. Clin. Invest. (1999) 103:1223–1225.
   PubMed Web of Science ®Google Scholar